Exciting News! Our Latest Published Paper Offers Promising Solutions for Pancreatic Cancer Treatment, Diagnostics, and Applications in ADC and ARC!
We are thrilled to announce the publication of our paper, “Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy,” in the prestigious Journal of Medicinal Chemistry. Led by Dr. Chi-Jiun Peng, our Director of Process Development and CMC, this research brings us closer to addressing the unmet needs in pancreatic cancer.
We are committed to advancing innovative solutions for challenging diseases. This groundbreaking research represents another significant step forward in our mission to transform pancreatic cancer treatment and improve patient outcomes.
Link to article: